Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

Susan Branford, Zbigniew Rudzki, Ian Parkinson, Andrew Grigg, Kerry Taylor, John F. Seymour, Simon Durrant, Peter Browett, Anthony P. Schwarer, Chris Arthur, John Catalano, Michael F. Leahy, Robin Filshie, Kenneth Bradstock, Richard Herrmann, David Joske, Kevin Lynch, Tim Hughes

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Mutations within the BCR-ABL kinase domain in imafinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Quantitative polymerase chain reaction (RQ-PCR) results of BCR-ABL mRNA were correlated with mutation analysis in 214 patients treated with imatinib. We determined whether there was a difference in the incidence of mutations between the patients with a more than 2-fold rise in BCR-ABL and patients with stable or decreasing levels. Of the 56 patients with a more than 2-fold rise, 34 (61%) had detectable mutations (median rise, 3.0-fold; 25th-75th percentiles, 2.3-5.2). In 31 (91%) of these 34 patients, the mutation was present at the time of the rise and became detectable within 3 months in the remaining patients. Only 1 (0.6%) of 158 patients with stable or decreasing BCR-ABL levels had a detectable mutation, P less than .0001. Thus, a more than 2-fold rise identified 34 (97%) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations.

LanguageEnglish
Pages2926-2932
Number of pages7
JournalBlood
Volume104
Issue number9
DOIs
Publication statusPublished - 1 Nov 2004
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Branford, Susan ; Rudzki, Zbigniew ; Parkinson, Ian ; Grigg, Andrew ; Taylor, Kerry ; Seymour, John F. ; Durrant, Simon ; Browett, Peter ; Schwarer, Anthony P. ; Arthur, Chris ; Catalano, John ; Leahy, Michael F. ; Filshie, Robin ; Bradstock, Kenneth ; Herrmann, Richard ; Joske, David ; Lynch, Kevin ; Hughes, Tim. / Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. In: Blood. 2004 ; Vol. 104, No. 9. pp. 2926-2932.
@article{cc1bbf6f1b29438c8a26022380a61bf4,
title = "Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations",
abstract = "Mutations within the BCR-ABL kinase domain in imafinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Quantitative polymerase chain reaction (RQ-PCR) results of BCR-ABL mRNA were correlated with mutation analysis in 214 patients treated with imatinib. We determined whether there was a difference in the incidence of mutations between the patients with a more than 2-fold rise in BCR-ABL and patients with stable or decreasing levels. Of the 56 patients with a more than 2-fold rise, 34 (61{\%}) had detectable mutations (median rise, 3.0-fold; 25th-75th percentiles, 2.3-5.2). In 31 (91{\%}) of these 34 patients, the mutation was present at the time of the rise and became detectable within 3 months in the remaining patients. Only 1 (0.6{\%}) of 158 patients with stable or decreasing BCR-ABL levels had a detectable mutation, P less than .0001. Thus, a more than 2-fold rise identified 34 (97{\%}) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations.",
author = "Susan Branford and Zbigniew Rudzki and Ian Parkinson and Andrew Grigg and Kerry Taylor and Seymour, {John F.} and Simon Durrant and Peter Browett and Schwarer, {Anthony P.} and Chris Arthur and John Catalano and Leahy, {Michael F.} and Robin Filshie and Kenneth Bradstock and Richard Herrmann and David Joske and Kevin Lynch and Tim Hughes",
year = "2004",
month = "11",
day = "1",
doi = "10.1182/blood-2004-03-1134",
language = "English",
volume = "104",
pages = "2926--2932",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

Branford, S, Rudzki, Z, Parkinson, I, Grigg, A, Taylor, K, Seymour, JF, Durrant, S, Browett, P, Schwarer, AP, Arthur, C, Catalano, J, Leahy, MF, Filshie, R, Bradstock, K, Herrmann, R, Joske, D, Lynch, K & Hughes, T 2004, 'Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations', Blood, vol. 104, no. 9, pp. 2926-2932. https://doi.org/10.1182/blood-2004-03-1134

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. / Branford, Susan; Rudzki, Zbigniew; Parkinson, Ian; Grigg, Andrew; Taylor, Kerry; Seymour, John F.; Durrant, Simon; Browett, Peter; Schwarer, Anthony P.; Arthur, Chris; Catalano, John; Leahy, Michael F.; Filshie, Robin; Bradstock, Kenneth; Herrmann, Richard; Joske, David; Lynch, Kevin; Hughes, Tim.

In: Blood, Vol. 104, No. 9, 01.11.2004, p. 2926-2932.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

AU - Branford, Susan

AU - Rudzki, Zbigniew

AU - Parkinson, Ian

AU - Grigg, Andrew

AU - Taylor, Kerry

AU - Seymour, John F.

AU - Durrant, Simon

AU - Browett, Peter

AU - Schwarer, Anthony P.

AU - Arthur, Chris

AU - Catalano, John

AU - Leahy, Michael F.

AU - Filshie, Robin

AU - Bradstock, Kenneth

AU - Herrmann, Richard

AU - Joske, David

AU - Lynch, Kevin

AU - Hughes, Tim

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Mutations within the BCR-ABL kinase domain in imafinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Quantitative polymerase chain reaction (RQ-PCR) results of BCR-ABL mRNA were correlated with mutation analysis in 214 patients treated with imatinib. We determined whether there was a difference in the incidence of mutations between the patients with a more than 2-fold rise in BCR-ABL and patients with stable or decreasing levels. Of the 56 patients with a more than 2-fold rise, 34 (61%) had detectable mutations (median rise, 3.0-fold; 25th-75th percentiles, 2.3-5.2). In 31 (91%) of these 34 patients, the mutation was present at the time of the rise and became detectable within 3 months in the remaining patients. Only 1 (0.6%) of 158 patients with stable or decreasing BCR-ABL levels had a detectable mutation, P less than .0001. Thus, a more than 2-fold rise identified 34 (97%) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations.

AB - Mutations within the BCR-ABL kinase domain in imafinib-treated chronic myeloid leukemia (CML) are the main mechanism of acquired resistance. The early detection of mutations should provide clinical benefit by allowing early intervention. Quantitative polymerase chain reaction (RQ-PCR) results of BCR-ABL mRNA were correlated with mutation analysis in 214 patients treated with imatinib. We determined whether there was a difference in the incidence of mutations between the patients with a more than 2-fold rise in BCR-ABL and patients with stable or decreasing levels. Of the 56 patients with a more than 2-fold rise, 34 (61%) had detectable mutations (median rise, 3.0-fold; 25th-75th percentiles, 2.3-5.2). In 31 (91%) of these 34 patients, the mutation was present at the time of the rise and became detectable within 3 months in the remaining patients. Only 1 (0.6%) of 158 patients with stable or decreasing BCR-ABL levels had a detectable mutation, P less than .0001. Thus, a more than 2-fold rise identified 34 (97%) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations.

UR - http://www.scopus.com/inward/record.url?scp=20844447330&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-03-1134

DO - 10.1182/blood-2004-03-1134

M3 - Article

VL - 104

SP - 2926

EP - 2932

JO - Blood

T2 - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -